Neoplasias hepáticas malignas: 1.a parte. Hepatocarcinoma: papel de la biopsia hepática, estudios de inmunohistoquímica y otros aspectos importantes

  • Rocio del Pilar López Panqueva
Palabras clave: Tumores hepáticos malignos, hepatocarcinoma, carcinoma hepatocelular, nódulos displásicos, hepatocarci- noma fibrolamelar, biopsia hepática percutánea, biopsia por aspiración, inmunohistoquímica

Resumen

Continuamos con la revisión de los tumores hepáticos. Nos referiremos a los tumores hepáticos primarios malignos más frecuentes. Tal como lo mencionamos anteriormente, los tumores malignos hepatobiliares son un espectro de tumores invasivos que reciben su nombre dependiendo de su célula de origen. De acuerdo con la Agencia Internacional para el Estudio del Cáncer (IARC), los tumores hepáticos malignos constituyen la segunda causa de muerte en el mundo, con aproximadamente 745 000 muertes/año (1). Al igual que en el artículo anterior, el objetivo es identificar aquellos aspectos más relevantes de estas neoplasias, en especial los hallazgos morfológicos que generan mayor problema diagnóstico en la utilidad de los estudios de inmunohistoquímica y sus diagnósticos diferenciales. La primera parte de esta revisión se centrará en el hepatocarcinoma, el más frecuente de los tumores he- páticos epiteliales malignos, algunas de sus variantes y sus lesiones precursoras. También en el controvertido papel de la biopsia hepática para su diagnóstico. 

Biografía del autor/a

Rocio del Pilar López Panqueva
Médica patóloga. Hospital Universitario Fundación Santa Fe de Bogotá, Sección Anatomía Patológica. Profesora, Facultad de Medicina, Universidad de los Andes. Bogotá, Colombia. 

Citas

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.

Wallace MC, Preen D, Jeffrey GP, Adams LA. The Evolving epidemiology of hepatocellular carcinoma: a global perspec- tive. Expert Rev Gastroenterol Hepatol. 2015;1:1-15.

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69.

Suzuki Y, Imai K, Takai K, et al. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J Cancer Res Clin Oncol. 2013;139(5):845-52.

Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Review of Gastroenterology & Hepatology. 2014;8(1):63-82.

Suarez I, Uribe D, Jaramillo CM, Osorio G, Pérez JC, López R, et al. Wnt/β-catenin signaling pathway in hepa- tocellular carcinomas cases from Colombia. Ann Hepathol. 2015;14(1):54-64.

Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013;22(3):305-10.

Navas MC, Suárez I, Carreño A, Uribe D, Ríos WA, Cortés- Mancera F, et al. Hepatitis B and hepatitis C infection bio- markers and TP53 mutations in hepatocellular carcinomas from Colombia. Hepat Res Treat. 2011;2011:582945.

Vilarinho S, Taddei T. Therapeutic strategies for hepatoce- llular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol. 2015;13(2):219-34.

Deepali Jain. Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S67-73.

Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detec- ted in cirrhosis at screening US. Radiology. 2015;141132.

Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, con- troversies and approach to diagnosis. Cytopathology. 2011;22(5):287-305.

Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, et al. The role of interventional radiology in the management of hepatocellular carcinoma. Current Oncology. 2014;21(3):480-92.

Wang P, Meng ZQ, Chen Z, et al. Diagnostic value and com- plications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome. A study based on 3011 patients in China. Eur J Surg Oncol. 2008;34:541-6.

Stigliano R, Marelli L, Yu D, et al. Seeding following percuta- neous diagnostic and therapeutic approaches for hepatoce- llular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33:437-47.

Kuo FY, Chen WJ, Lu SN, Wang JH, Eng HL. Fine nee- dle aspiration cytodiagnosis of liver tumors. Acta Cytol. 2004;48(2):142-8.

Castro-Villabón D, Avello Y, Ruiz N, Rodríguez-Urrego PA. Implementation of routine thromboplastin-plasma cell block technique in the evaluation of non-gynecologic specimens: A methodologic comparison with conventional cytology. J Microscopy Ultrastructure. 2014;2(3):177-81.

Jain D. Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S67-73.

Compagnon P, Grandadam S, Lorho R, et al. Liver trans- plantation for hepatocellular carcinoma without preopera- tive tumor biopsy. Transplantation. 2008;86:1068-76.

International Consensus Group for Hepatocellular Neoplasia. International consensus on the pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular

Neoplasia. Hepatology. 2009;49:658-64.

Fuks D, Cauchy F, Fusco G, Paradis V, Durand F, Belghiti J. Preoperative tumour biopsy does not affect the oncolo- gic course of patients with transplantable HCC. J Hepatol. 2014;61(3):589-93.

Barbhuiya M, Bhunia S, Kakkar M, Shrivastava B, Tiwari PK, Gupta S. Fine needle aspiration cytology of lesions of liver and gallbladder: An analysis of 400 consecutive aspira- tions. J Cytol. 2014;31(1):20-4.

Saleh HA, Aulicino M, Zaidi SY, Khan AZ, Masood S. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel. Diagn Cytopathol. 2009;37(3):184-90.

Goodman ZD. Neoplasms of the liver. Modern Pathology. 2007;20:S49-60.

Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Mod Pathol. 2000;13(6):679-704.

Castro-Villabón D, Barrera-Herrera LE, Rodríguez-Urrego PA, Hudacko R, Vera A, Álvarez J, et al. Hepatocellular carcinoma with both fibrolamellar and classical compo- nents: an unusual morphological pattern. Case Rep Pathol. 2015;2015;609780.

Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepa- tocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18:438-45.

Geller SA, Dhall D, Alsabeh R. Application of immuno- histochemistry to liver and gastrointestinal neoplasms liver, stomach, colon, and pancreas. Arch Pathol Lab Med. 2008;132:490-9.

Krings G, Ramanchandran R, Jain D, Wu TT, Yeh MM, Torbenson M, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology. 2013;26:782-91.

Kandil SK, Cooper K. Glypican-3: a novel diagnostic mar- ker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125-9.

Yan BC, Gong C, Song J, Krausz T, Tretiakova M, et al. Arginase-1: a new immunohistochemical marker of hepa- tocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34(8):1147-54.

Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepa- tocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol. 2013;21(2):170-6.

Publicado
2016-11-03
Sección
Educación Continuada de Hepatopatología